# Polycystic Ovary Syndrome Gets New Name to Better Reflect the Condition
The medical community has renamed polycystic ovary syndrome (PCOS) to polycystic metabolic syndrome (PMOS). The change reflects a growing scientific understanding that PCOS involves far more than ovarian cysts.
PCOS affects roughly one in ten women of reproductive age, yet many remain undiagnosed or receive late diagnoses. The old name created confusion because not all people with the condition develop cysts, and the name emphasizes reproductive organs while obscuring the metabolic dysfunction at the condition's core.
The new terminology centers on metabolic problems, including insulin resistance, inflammation, and hormone imbalances that extend well beyond fertility issues. People with PCOS face elevated risks for type 2 diabetes, cardiovascular disease, and metabolic dysfunction throughout their lives.
Dr. Thalia Menendez, an endocrinologist at a major medical center, explained that the name shift encourages doctors to screen for metabolic complications earlier. When physicians think of PCOS purely as an ovarian condition, they may miss diagnosing insulin resistance or prediabetes in their patients.
The Rotterdam Criteria, the diagnostic standard used globally, already recognizes that PCOS requires a metabolic lens. Patients typically show two of three features: irregular periods, signs of excess androgens, and ovarian cysts on imaging. But the new name brings language in line with clinical reality.
Researchers working on PCOS terminology changes note that better naming improves patient outcomes. When patients understand their condition involves metabolic health, they become more engaged in lifestyle modifications like exercise and dietary changes that can slow disease progression.
The shift also benefits people who don't menstruate regularly or who don't seek care for reproductive reasons. A person experiencing unexplained weight gain